You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of the VirtualTAVR system for diagnostics and preventative strategies

    SBC: Dura LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Since the first procedure in there has been an explosive growth in transcatheter aortic valve replacement TAVR Up to date more than TAVR had been performed worldwide Despite the increased global experience with TAVR severe adverse events associated with TAVR have been extensively documented including annulus rupture coronary occlusion para ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Antimicrobial Microbead Containing Topical Gel for Burn Wound Disinfection

    SBC: LYNNTECH INC.            Topic: NIAID

    DESCRIPTION provided by applicant In the U S there are more than hospitalizations annually related to burn injury with more than of these admissions to the U S burn centers resulting in more than $ billion in healthcare costs Burn wounds may become infected through patient self infection from their own normal flora or by nosocomial infection between healthcare provider or fa ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. XRpro Radioactive Cesium Decorporation Agents

    SBC: Icagen, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation nuclear emergencies high priority for DHHS NIH NIAID DAIT and a critical need for the Strategic National Stockpile S ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Inhibitors Targeting Early Steps of Human Cytomegalovirus Replication

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Human cytomegalovirus HCMV infection is a major cause of morbidity and mortality in immunosuppressed patients especially recipients of solid organ or bone marrow transplants HCMV infection of neonates is associated with deafness mental retardation and mortality Although five anti viral drugs GCV val GCV CDV PFA Foscarnet have been approved and lice ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Mobile Health App to Reduce Diabetes in Latina Women with Prior Gestational Diabe

    SBC: Environment And Health Group, Inc.            Topic: NIMHD

    DESCRIPTION provided by applicant Hispanic women have the highest lifetime risk for type diabetes T DM A window of opportunity for preventing T DM exists for women with pregnancies complicated by gestational diabetes mellitus GDM Women with prior GDM face increased risk of T DM Hispanic women are at increased risk of GDM and those with GDM have higher relative risks for developing T D ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Picture Me Fit: Engaging Youth in Community-Based Prevention

    SBC: PREVENTION STRATEGIES, LLC            Topic: 600

    DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A novel broad-spectrum influenza vaccine

    SBC: KJ BIOSCIENCES LLC            Topic: NIAID

    DESCRIPTION provided by applicant Influenza viruses constantly undergo antigenic changes which pose great challenges for development of vaccines against influenza epidemics as well as pandemics There are at least known subtypes of influenza A viruses which fall into two broad phylogenetic groups Current trivalent inactivated vaccines TIV H H and B for seasonal influenza are not suit ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government